Company Overview
Company Type: Private Company
Website: www.stemcell.com
Number of Employees: 140
Year Founded: 1993
Total Amount Raised (CAD mm)†: 73.22
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
STEMCELL Technologies Canada Inc. develops cell culture media, cell separation systems, instruments, and other reagents to support research in the fields of immunology, hematology, neuroscience, mesenchymal stem cell, stem cell, and epithelial cell biology. It offers antibodies, buffers and solutions, cell culture media and supplements, cell dyes and detection assay kits, cell isolation products, cell storage media, cultureware and general supplies, cytokines, density gradient media, ELISAs, instruments and software, laboratory equipment, matrices and substrates, primary and cultured cells, small molecules, standardization tools, and tissue and cell culture dissociation reagents. The company also provides contract assay services, custom solutions, product and scientific support, and standardization tools. It offers tools for research on immune cells, embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neural stem cells, intestinal epithelial cells, mammary epithelial cells, airway epithelial cells, prostate epithelial cells, pancreatic cells, and endothelial cells. The company’s products are available online and through a distributor network. STEMCELL Technologies Canada Inc. was formerly known as STEMCELL Technologies, Inc. The company was founded in 1993 and is based in Vancouver, Canada with locations in North America, Europe, Asia, and Oceania.


Financial Information (Currency: CAD, in mm)
Total Revenue
 54.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 140
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Eaves, Allen C. 
Chief Executive Officer and President


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
1618 Station Street | Vancouver, BC | V6A 1B6 | Canada
Phone: 604-877-0713   Fax: 604-877-0704

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
BDC Capital Inc.
Feb-08-2018
Unknown
-
Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Stemcell Technologies Inc.
Stemcell Technologies Inc. engages in warehousing and shipping services. The company is based in Tukwila, Washington. Stemcell Technologies Inc. operates as a subsidiary of STEMCELL Technologies, Inc.

United States and Canada
Diversified Support Services
4.00
-
-
Stemsoft Software Inc.

-
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-25-2018
Apr-25-2018
Private Placement
Target
STEMCELL Technologies Canada Inc.


45.00
Feb-08-2018
Feb-08-2018
Private Placement
Target
STEMCELL Technologies Canada Inc.
BDC Capital Inc.

11.90
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-30-2023
Company Conference Presentations
STEMCELL Technologies Canada Inc. Presents at 8th CAR-TCR Summit, Aug-30-2023 12:00 PM
Apr-19-2022
Client Announcements
Applied Cells Enters into a Supply Agreement with STEMCELL Technologies on Reagent Kits for Use in a Next-Generation Solution for Cell Separation
Aug-18-2021
Client Announcements
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Dec-10-2020
Client Announcements
CollPlant and STEMCELL Technologies Enters into A Product Manufacturing and Supply Agreement
Oct-20-2020
Company Conference Presentations
STEMCELL Technologies Canada Inc. Presents at The New York Stem Cell Foundation Conference 2020, Oct-20-2020

Competitors
BioLife Solutions, Inc. (NasdaqCM:BLFS), Cambrex Corporation, CHEMICON International, Inc. (Acquired), Crucell N.V., EMD Millipore Corporation, Fisher Scientific International LLC, International Stem Cell Corporation (OTCPK:ISCO), Life Technologies Corporation, Lifeline Cell Technology, LLC, Lineage Cell Therapeutics, Inc. (NYSEAM:LCTX), Lonza Group AG (SWX:LONN), Promocell Bioscience Alive Gmbh Biomedizinische Produkte, ReNeuron Group plc (AIM:RENE), Sigma-Aldrich Corporation, VWR International, LLC, Zen-Bio, Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Insight Partners
The Insight Partners Research Team
Sep 06, 2023 04:34 AM
STEMCELL Technologies Canada Inc.
Steroplast Healthcare Ltd in Global Self-Adherent Wraps Market to 2028
Notes
5
The Insight Partners
The Insight Partners Research Team
Sep 06, 2023 04:33 AM
STEMCELL Technologies Canada Inc.
STEMCELL Technologies Inc. in Global Organoids Market to 2028
Notes
6
GlobalData

Dec 19, 2017 06:29 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc
Reports
25
GlobalData

Oct 12, 2017 12:10 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Sep 14, 2017 06:25 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc
Reports
23
GlobalData

Sep 12, 2017 07:36 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Jun 29, 2017 05:23 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc
Reports
23
GlobalData

May 17, 2017 05:39 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21
GlobalData

Mar 31, 2017 05:50 AM
STEMCELL Technologies Canada Inc.
STEMCELL Technologies to Launch CloneR to Facilitate Genome Editing of Human Pluripotent Stem Cells
Reports
2
GlobalData

Mar 20, 2017 05:48 AM
STEMCELL Technologies Canada Inc.
StemCell Technologies Inc
Reports
20


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AggreWell 400 Plates, BD Matrigel hESC-qualified Matrix, MesenCult-ACF Medium, MethoCult Express, MTeSR 1 Maintenance Medium, STEMdiff (Future), TeSR 2, TeSR-E8 (Future)

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Eaves, Allen C. 
Chief Executive Officer and President
604-877-0713
604-877-0704
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
